BAX vs GMED: stock comparison and AI forecast
Baxter International Inc (BAX) and Globus Medical Inc (GMED) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BAX Baxter International Inc
- Market Cap
- $12.52B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
GMED Globus Medical Inc
- Price
- $79.46 -12.3% · 6M
- Market Cap
- $10.67B
- P/E Ratio
- 22.5x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- BAX is 1.2 times larger than GMED by market capitalization ($12.52B against $10.67B).
- BAX carries 1.99 times debt per unit of equity, against 0.11 times for GMED.
- BAX yields 0.81% in dividends; GMED pays none.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BAX | GMED |
|---|---|---|
| Market Cap | $12.52B | $10.67B |
| P/E Ratio | – | 22.51x |
| P/B Ratio | 1.93x | 5.37x |
| Dividend Yield | 0.81% | – |
| EPS | $-1.21 | $3.53 |
| Book Value/Share | $12.58 | $14.79 |
| Revenue/Share | $22.46 | $23.42 |
| FCF/Share | – | $5.63 |
Profitability & Margins
| Metric | BAX | GMED |
|---|---|---|
| ROE | -11.1% | – |
| ROA | -3.7% | – |
| ROIC | -1.4% | – |
| Gross Margin | 30.1% | 68.5% |
| Operating Margin | -1.9% | 54.8% |
| Net Margin | -6.2% | – |
| EBT Margin | -1.6% | 56.6% |
| Tax Rate | -231.0% | 18.9% |
Financial Health
| Metric | BAX | GMED |
|---|---|---|
| Current Ratio | 1.79x | 4.62x |
| Quick Ratio | 1.19x | 2.93x |
| D/E Ratio | 1.99x | 0.11x |
| Financial Leverage | 2.99x | – |
| Interest Coverage | -2.5x | 94.4x |
| Working Capital | $3.02B | $1.74B |
Cash Flow
| Metric | BAX | GMED |
|---|---|---|
| Operating Cash Flow | $1.64B | $910M |
| Free Cash Flow | – | $756M |
| Capital Spending | – | -$155M |
| OCF Growth YoY | 119.0% | 36.0% |
| FCF Growth YoY | – | 43.3% |
| FCF/Sales | – | 24.0% |
| CapEx/Sales | – | 4.9% |
Operational Efficiency
| Metric | BAX | GMED |
|---|---|---|
| Asset Turnover | 0.60x | – |
| Receivables Turnover | 6.5x | 4.5x |
| Inventory Turnover | 3.5x | 1.2x |
| Fixed Assets Turnover | 4.0x | 5.9x |
| Days Sales Outstanding | 56 days | 80 days |
| Days Inventory | 103 days | 299 days |
| Payables Period | 46 days | 39 days |
| Cash Conversion Cycle | 113 days | 340 days |
Income Statement
| Metric | BAX | GMED |
|---|---|---|
| Total Revenue | $11.61B | $3.14B |
| Operating Income | -$221M | $640M |
| Net Income | -$723M | – |
| R&D Expense | $519M | $147M |
| SG&A Expense | $2.95B | $1.22B |
| Cost of Goods Sold | $8.12B | $989M |
Dividend & Shareholder Information
| Metric | BAX | GMED |
|---|---|---|
| Dividends Per Share | $0.20 | – |
| Shares Outstanding | 517M | 134M |
| EPS Growth | – | 75.6% |
BAX vs GMED: stock comparison and AI forecast
Which is bigger, BAX or GMED?
BAX is 1.2 times larger than GMED by market capitalization ($12.52B against $10.67B).
Which one does Intratio's AI model rank higher, BAX or GMED?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.